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Developing Effective and Efficient care pathways
in chronic Pain: DEEP study protocol
Justin Durham1,2*, Matthew Breckons1, Vera Araujo-Soares1, Catherine Exley1, Jimmy Steele1,2 and Luke Vale1
Abstract
Background: Pain affecting the face or mouth and lasting longer than three months (“chronic orofacial pain”,
COFP) is relatively common in the UK. This study aims to describe and model current care pathways for COFP
patients, identify areas where current pathways could be modified, and model whether these changes would
improve outcomes for patients and use resources more efficiently.
Methods/Design: The study takes a prospective operations research approach. A cohort of primary and secondary
care COFP patients (n = 240) will be recruited at differing stages of their care in order to follow and analyse their
journey through care. The cohort will be followed for two years with data collected at baseline 6, 12, 18, and 24
months on: 1) experiences of the care pathway and its impacts; 2) quality of life; 3) pain; 4) use of health services
and costs incurred; 5) illness perceptions. Qualitative in-depth interviews will be used to collect data on patient
experiences from a purposive sub-sample of the total cohort (n = 30) at baseline, 12 and 24 months. Four separate
appraisal groups (public, patient, clincian, service manager/commissioning) will then be given data from the pathway
analysis and asked to determine their priority areas for change. The proposals from appraisal groups will inform an
economic modelling exercise. Findings from the economic modelling will be presented as incremental costs, Quality
Adjusted Life Years (QALYs), and the incremental cost per QALY gained. At the end of the modelling a series of
recommendations for service change will be available for implementation or further trial if necessary.
Discussion: The recent white paper on health and the report from the NHS Forum identified chronic conditions as
priority areas and whilst technology can improve outcomes, so can simple, appropriate and well-defined clinical care
pathways. Understanding the opportunity cost related to care pathways benefits the wider NHS. This research develops
a method to help design efficient systems built around one condition (COFP), but the principles should be applicable
to a wide range of other chronic and long-term conditions.
Keywords: Orofacial pain, Health economics, Quality of life, Qualitative methods, Chronic pain, Care pathways
Background
Chronic pain is a distressing problem for patients and
is difficult, and sometimes distressing, to manage for
clinicians [1-4]. Chronic orofacial pain (COFP) affects a
reported 13% of the UK population, and is particularly
complex and distressing for patients [5-9]. Diagnosis and
treatment for COFP conditions is slowly improving
through the institution of new, targeted, diagnostic tools
[10] and advances in genomics [11], but current care
pathways do not seem to maximise therapeutic potential
and paradoxically may worsen COFP [6,12].
COFP patients are known to use more healthcare
resource compared to other dental patients [13-17],
but what is unknown is why, or where, this utilisation
occurs and how effective it is. Previous research
[1,6,12,13] seems to suggest that a large proportion of this
resource utilisation may occur as a result of inadequate
care pathways for patients with COFP: cyclical referrals
accompanied by multiple and unnecessary consultations
which often only serve to increase confusion and
sometimes worsen the patient’s complaint [6]. This is
a costly process for both the patient and the health
service and therefore in addition to delivering more
accurate diagnoses and treatment there is an urgent
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need to understand how and where services can be stream-
lined in order to get patients to the most appropriate care
effectively and efficiently.
A simplistic unidimensional assessment of the costs of
care pathways is insufficient to capture the biopsychosocial
dynamic relationship of COFP and the care received [18]. A
“whole systems perspective” [19] is required in order to
assess current care pathways and produce patient centred
services “designed around patient’s needs” [20]. This will
help achieve one of the recent recommendations of the
recent national pain audit in the UK, which is to “research…
optimal models of care for people with chronic pain,
including economic modelling” [21]. Without identifying
where the negative economic, biomedical, and psychosocial
impacts exist on the current care pathway from both the
consumer and the providers’ perspectives, it is impossible
to model new pathways that provide appropriate care in a
patient-centred, efficient, efficacious and expedient manner.
Aims and objectives
This study will describe and model current care pathways
for COFP patients, identify areas where the current
pathways could be modified, and model the estimated
impact of change to determine what changes would
improve outcomes for patients and use resources more
efficiently.
Specifically it will:
Phase 1
i) Develop a map of COFP patients’ journeys through
care and understand their experiences of the care
pathway using qualitative in-depth interviews.
ii) Identify the impacts of the various stages of care
pathways on: individual’s pain (West Haven Yale
Multidimensional Pain Inventory, WYMPI [22];
Graded Chronic Pain Scale, GCPS [23]); quality of
life, (EQ-5D) and the value that patients attach to
the various stages of their care pathway [24]; use of
health service and patient costs (use of health
service and patient costs questionnaire [25]); illness
perceptions (Revised illness perceptions
questionnaire, IPQ-R [26]).
Phase 2
iii)Develop a model based upon the care pathways
reflecting key events (e.g. referrals, use of services,
impact on pain and daily living) and use this model
to estimate the cost and outcomes (e.g. level of pain,
quality of life).
iv)Use the data gathered from objectives i to iii and
work with stakeholders, to identify priority areas
where the current pathway might be changed and
model the impact of the potential changes on costs,
outcomes and cost-effectiveness of care for COFP.
v) Use the results of (i-iv) above develop
recommendations for practice and future research
Methods/Design
We propose to capture data across the journey through
care for COFP patients. This journey will start with the
experience of pain and the individual will seek help from
the health service, most frequently through primary care,
but not exclusively so. The care journey may, for a minority,
be a short one, but the current literature suggests that
multiple healthcare providers may be consulted about the
condition and the journey may not be as linear as depicted
by Figure 1 [6,12,13,21]. If this were the case it would mean
that to capture the entirety of some individuals’ care
pathway(s) might take several years, which is impractical
for a number of reasons. This study proposes to solve this
problem by purposively sampling individuals suffering
from COFP along the continuum of care from initial
experience of pain through to a final outcome which may
be successful treatment, or the acknowledgement no more
can be done (Figure 1). In this manner we will be able to
capture data from all aspects of the care journey and
pathway for two years, which will result in some individuals
describing whole journeys (Figure 1 – dark plus light grey
boxes) and some describing particular aspects or points of
the care pathway (Figure 1 – dark grey boxes).
This data collection across the continuum will allow a
complete picture of the possible care pathways for COFP
patients to be built. Data collection will be accomplished
through qualitative and quantitative methods with the
qualitative data helping explain any apparent relationships
in the quantitative data.
Phase 1 – Recruitment, observation, recording,
and mapping the current pathway(s)
Methods
Patients will be recruited from Primary and Secondary care
in the North East of England. Primary care recruitment
will take place from 25 medical practices and 10 dental
practices from diverse socioeconomic areas (Figure 2).
Secondary care patients will be recruited from a variety of
clinics in the local dental and medical hospitals: neurology,
oral and maxillofacial surgery, dental emergency clinic, oral
medicine, and restorative dentistry.
Using a total sample size of 200, with a Type I error of
5%, we can, with 80% power, detect an effect size of 0.4
within our data (Two-tailed). This represents a moderate
effect size [28] on which to base our sample size because
a smaller effect size, if detected, would be unlikely to
mandate significant changes in the healthcare system.
Allowing for 20% attrition provides a final sample size of
240. This attrition rate is realistic because of our previous
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experience with longitudinal data collection with patients
suffering from COFP showing a high dropout rate.
Inclusion and exclusion criteria
Participants will be over the age of eighteen. Orofacial pain
will have been present for greater than or equal to three
months [29]. Using a validated dual baseline-screening
questionnaire (BSQ1) [30,31] the participants will be cate-
gorised post-initial recruitment to assign their orofacial pain
to a neurological/vascular (from nerves or blood vessels),
Dentoalveolar (from tooth or tooth bearing structure), or
Temporomandibular disorder/musculoskeletal cause. The
sample will be stratified by care sector and gender.
Where a specialist clinical diagnosis is available which
suggests a negative screening result from the BSQ1 is a
false negative the Chief Investigator (CI) will review the
sub-diagnosis automatically generated by the screening
questionnaire along with the individual’s clinical diagno-
sis. The CI will then only include the patient in the study
if the sub diagnosis or specialist clinical diagnosis is
part of the group of conditions being studied: all types
of headache, temporomandibular disorders (TMDs),
neuralgias, burning mouth syndrome, traumatic neu-
ropathies, and persistent dentoalveolar pain disorder
(atypical odontalgia).
The exclusion criteria are that: 1) an individual
lacks the capacity to give informed consent for any
reason; 2) an individual is categorised by the screening
questionnaire as only having dentoalveolar pain, which
is not part of the group of conditions that comprise
COFP; 3) an individual is unable to communicate
complex constructs in English given the qualitative
aspects of the overall study.
Recruitment
The participating clinical and or research team will both
prospectively and retrospectively identify individuals
eligible to be included in the study on the initial basis of:
their age, the duration of their complaint, and presumed
diagnosis. Electronic and paper adverts advertising the
study will also be placed within the practices participating
and any allied clinical facilities such as pharmacies
they use. Adverts will also be placed in public places
and in the local press if necessary. The advert provides the
contact details for the study team and, if appropriate, the
individual contacting the study team will be recruited as
described below.
For prospective recruitment the research or clinical
team will give the patient a short standardised verbal
description of the study and ask if the patient is interested
in being involved. Standardised recruitment pro forma will
be used to record those who are interested in participating
in the study and those who decline in order to facilitate an
analysis of both those who decline and eventually those
who fail to respond or complete the study. Those who are
interested in participating will be issued with a phase
1 patient pack, which includes: a patient information sheet,
phase 1 consent form and the BSQ1.
For retrospective recruitment standardised letters from
the patient’s primary care practitioner explaining the
study will be sent out to patients seen within the last
year with pain fitting the inclusion criteria to ascertain if
Figure 1 Schematic of patient journey, data capture, and use of data from study.
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they are interested in taking part in the study. Patients con-
tacted in this manner will be asked to contact the research
team if they are interested in participating and then the re-
search team will give a standardised verbal explanation of
the study by phone, complete the recruitment proforma,
and then send out the phase 1 patient pack.
In both prospective and retrospective recruitment, a
trained member of the research team will contact those
interested within the next fortnight by telephone, or at
their next clinic appointment, in order to complete
the BSQ1 verbally if the individual is still willing to
participate. The BSQ1 is completed by the researcher
in accordance with the participant’s responses within
Excel (Excel v10, Microsoft Corporation, Redmond, WA,
USA) and gives an immediate outcome in relation to the
inclusion criteria. Those screening positive and giving
informed consent, will then be enrolled in the study.
Those who withhold consent will be thanked for their
interest and will not be enrolled. Those who screen
negative will be thanked for their interest and will not
be enrolled unless a false negative is suspected whereby the
CI will review all available results for the individual. Those
enrolled in the study, after screening positive and giving
consent, will be contacted by the research team at a
time and location convenient to them to conduct base-
line data collection. Any withdrawals from the enrolled
cohort will be noted along with age, gender, BSQ1 classifi-
cation, and the broad reason given for their withdrawal.
Data collection
All participants (n = 240) will complete a baseline
structured interview (Case report form [CRF]) with a
trained member of the research team, either by phone or
face-to-face, in order to: a) capture baseline sociodemo-
graphic data; b) capture data about their pain to that
point (duration, treatment received and its effectiveness,
healthcare practitioners seen); c) ensure their comprehen-
sion of the instruments to be used over the next two years.
We have identified the impact of pain, quality of life, and
costs as the three most appropriate measures of success in
a healthcare system attempting to manage COFP. The
instruments used to gather quantitative data on the impact
and degree of pain, quality of life, and costs of illness at the
varying data collection points (Figure 3, Table 1) will be:
! A quality of life instrument will be issued at each of
the six monthly data collection points. This will
be the EQ-5D-5 L [24]). At baseline two reference
periods will be used for the EQ-5D “last month”
and “today” (Questionnaire 1a), thereafter only the
standardised reference period of “today” will be used
(Questionnaire 1b).
! Multidimensional pain measures – those used will
be the Graded Chronic Pain Scale (GCPS) [32]
and the West-Haven Yale Multidimensional Pain
Inventory (WYMPI version 3) [22]. The baseline
questionnaire 2a contains both the GCPS and the
Pain impact and Spousal interactions subscales of
the WYMPI, but questionnaire 2b used sequentially
thereafter omits the final subscale of the WYMPI
relating to spousal interactions in order to reduce
respondent burden.
! Cost of illness instruments – To reduce respondent
burden we will issue a “Use of services and
0
1
2
3
4
5
6
10 20 30 40 50 60 70 80 90 100
n
IMD Decile
Dental practices
Medical practices
Figure 2 Sociodemographic of practices involved in study. This figure is calculated by using the 2010 UK census data available at http://
neighbourhood.statistics.gov.uk/dissemination/. This census defined 32482 small geographic areas in England each consisting of approximately
1500 people (Lower super-output areas [LSOA]). Each LSOA was assessed and scored according to standardised criteria across 38 domains and
then ranked from the best score (rank 1) to the worst (32482). These 38 domains included income, health, and employment [27] and were com-
bined to produce a composite “index of multiple deprivation” (IMD) which was ranked in the same manner. The deciles in the figure above repre-
sent the rounded percentage ranking with lower deciles equating to worse deprivation according to IMD score.
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productivity” questionnaire at each six monthly data
collection points (Questionnaire 3) and a one-off
“Time and Travel” questionnaire (Questionnaire 5) [25]
at fourteen months into the study. Questionnaire 3 has
two versions in order to try and reduce respondent
burden: version “a” for administration at baseline, and
version “b” for sequential administration thereafter.
Version “b” is almost identical to the “a” version other
than the omission of some questions that cannot
change from baseline for example, “occupation when
pain started”, and giving options to record sections as
“no change” since last administration. Illness percep-
tions, anxiety and depression will also be briefly
examined in order to help profile the study cohort.
This will be accomplished through using the IPQ-R
and PHQ-4 in questionnaire 4 which will be issued at
baseline, twelve and twenty-four months [26,33-36].
A notes-based analysis of consultation, prescription, and
referral histories will supplement the self-complete data
where necessary and telephone interviews will be held
with patients whose data requires further clarification.
Throughout the quantitative data collection interim
analyses will be conducted on the immature data sets
to help identify and explain missing data, and shift
the analysis burden.
Any individuals whose data has not been received
fourteen days after the instruments were posted to them
will be followed up using a standardised operating protocol:
reminder letter, then telephone call, and then contact
with nominated secondary point of contact if none of
the previous modalities of contact have been successful in
reaching the individual or their voicemail. An individual
will be assumed to have withdrawn in absentia ten days
after leaving a message with a voicemail or contacting the
secondary point of contact; should they subsequently
contact the research team and express a desire to
continue all efforts will be made, as far as reasonably
practical, to facilitate this.
Qualitative interviews will take place with a purposive
sub-sample (n = 30) of the total cohort. The sub-sample
will be taken using: gender; strata for time in care; type of
care environment; origin of COFP (Table 2). Telephone or
face-to-face qualitative interviews will be conducted at
baseline with this sub-sample by trained and experienced
interviewers using a flexible evolving topic guide. It is
planned that the same sub-sample will be interviewed
again at twelve months and twenty-four months by tele-
phone or face-to-face in order to examine any further ex-
periences or altered perceptions. Data collection and
analysis will follow the principles of the constant
comparative method [37] whereby data collection and
analysis occur concurrently and continue until saturation,
which will allow us to add to our sample should
interesting issues arise. The interviews aim to build an
understanding of: the illness the individual is experien-
cing, the journey(s) through care, and any apparent
relationships in the quantitative data.
Analysis
Data on use of services (Q3a, 3b and 5) will be used to
calculate costs by combining information on resource
use with unit costs either developed as study specific
estimates or obtained from routinely available sources
for example the unit costs of health care [38], the British
Initial recruitment prior to screening for eligibility
Patient with three or more months orofacial pain.     
Verbal description and initial recruitment prior to 
screening
Complete recruitment proforma and send to team
Follow-up and enrollment
Verbal completion of eligibility Phase 1 Baseline 
Screening Questionnaire (BSQ1)
Confirm eligibility via BSQ1
Written consent
Data collection 
Baseline: Case-report form (CRF) Questionnaires 1a, 2a, 
3a, 4
6 months: Questionnaires 1b, 2b, 3b
12 months: Questionnaire 4 in addition to 1b, 2b, 3b
14 months: Questionnaire 5 only
18 months: Questionnaires 1b, 2b, 3b
24 months: Questionnaire 4 in addition to 1b, 2b, 3b
Figure 3 Study flowchart for Phase 1.
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National Formulary for medications [39]. The EQ-5D 5 L
responses will be converted into health state utilities using
tariffs currently under development or cross-walked to the
pre-existent EQ-5D-3 L UK population health tariffs [40,41]
and will estimate quality adjusted life years (QALYs [42]).
Data from GCPS and WYMPI (Q2a and 2b) will be
used in order to build a sequential multidimensional
picture of the pain’s impact on individuals. As GCPS
has been shown to be predictive of outcome in one
specific type of COFP (TMDs [23]) it will be examined
specifically to see if it provides a good predictor of
outcome in primary and or secondary care. The omission
of the spousal interactions section from WYMPI after
baseline administration will mean that this cannot be
examined in relation to change, but it will help categorise
our sample at baseline.
The IPQ-R will give us sequential data on the patient’s
lay perception of their symptoms’: identity, cause, severity,
consequences, treatment/control. This instrument will
also allow us to assess at defined points during their care
pathway the emotional impact of their illness as well as
their understanding (perceived coherence) of their illness.
Scores from the questionnaires are likely to need to be
transformed to allow one-way and repeated ANOVA to
determine if there are significant differences in cost across
quality of life scores and pain. Follow-up regression analysis
will then be used to determine the multivariate predictors
of these differences including GCPS, care sector, education,
and other sociodemographic variables. This data analysis
will then help inform the appraisal groups.
Phase two methods: pathway analysis and
priority setting
The aims of Phase 2 are:
1) To develop a model based upon the care pathways
reflecting key events (e.g. referrals, use of services,
impact on pain and daily living) and use this model
to estimate the cost and outcomes (e.g. level of pain,
quality of life).
2) To use the data gathered and work with
stakeholders, to identify areas where the current
pathway might be changed and model the impact
of the potential changes on costs, outcomes and
cost-effectiveness of care for COFP.
Methods
The analysis of the qualitative data will be used to
assemble the framework (map) of current experiences of
the journey through care using an iterative methodology
to record recurring emergent experiences against the
generic stages of the patients’ journeys [6]. The qualitative
data will be used to highlight any areas of concern for the
sample on the map of the current journey through care
with the quantitative data used alongside the qualitative
data to help quantify the degree of impact and identify
areas that, if changed, may produce the most benefit to
the patients and health service. This will be an iterative
process that will produce an understanding and inform a
Table 2 Purposive subsampling criteria
Stratification Details
Gender Attempt to gain a 1:1 ratio of gender in
subsample
Care environment Attempt to gain a 1:1 ratio of those in primary care
at baseline and those in secondary care at baseline
Time in care Attempt to gain a subsample that contains three
broad groups:
First experience of COFP (maximum 6–12 month history)
Moderate experience of COFP (13–23 month history)
Long experience of COFP (>23 month
history)
Origin of COFP Attempt to get an equal representation of
musculoskeletal and neuropathic/vascular origins
in sample
Table 1 Phase 1 questionnaire administration timetable
Issued at:
Questionnaire Recruitment Baseline 6 M 12 M 14 M 18 M 24 M
BSQ1 X
CRF X
EQ-5D (Q1a) X
EQ-5D (Q1b) X X X X
GCPS & WHYMPI (Q2a) X
GCPS & WHYMPI (Q2b) X X X X
Baseline use of services and productivity (Q3a) X
Ongoing use of services and productivity (Q3b) X X X X
IPQ-R and PHQ-4 (Q4) X X X
Time and travel questionnaire (Q5) X
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model that will be developed to describe the care pathways
experienced.
The map and quantitative longitudinal data will in
themselves illustrate areas of high cost and poor outcome
(pain, quality of life) but the discussion on which areas of
the pathway are a priority to change will be conducted
with four separate appraisal groups: public, patient,
clinician, and commissioning and managing groups,
each consisting of 5–8 members of a variety of ages
from the local area. COFP patients and the public (lay)
participants will be recruited from routine diagnostic
clinics in the Newcastle-Upon-Tyne Hospitals Trust using
a standardised PIS and consent form. The inclusion and
exclusion criteria for patients will mirror that of phase 1
using the same screening questionnaire. To be accepted as
a member of the public the following inclusion criteria
must be met through responding to a short screening
questionnaire:
! The individual in question nor their family have
on-going pain in their mouth and or face within the
last twelve months
! The individual in question nor their family are
health professionals
A standardised letter will be used to approach local
clinicians and service managers/commissioners at their
respective professional addresses. The letter will contain
the Patient Information Sheet (PIS) and consent form
and contact details for the research team.
The appraisal groups will be presented with the study
findings in a comprehensible annonymised form two
weeks prior to convening and upon convening will be
conducted in a focus group manner. The groups will be
recorded and transcribed verbatim, helping guide the
decisions on the priority areas in the current care pathway
to change in the subsequent economic modelling. Trained
facilitators using flexible and evolving topic guides will
undertake the focus groups. The groups will be digitally
recorded and transcribed verbatim. Qualitative analysis of
the focus group data will follow the same principles as
those described in Phase 1.
Phase three methods: economic modelling and
recommendations
The aim of phase three is:
1) Using the results of phase one and two, develop
recommendations for practice and future research
This phase consists of developing an economic
model based upon the care pathways determined in
phases 1 and 2. The model will describe the logical
and temporal sequence of events from first
presentation with COFP in primary care through
any subsequent management in both primary and
secondary care. The model will be developed in line
with best practice [43]. We anticipate that the model
may take the form of a Markov model but the
precise form of the model will be determined as part
of the project and will be chosen to fit the processes
modelled. The outputs of the model will be
cumulative costs and QALYs over a 5-year period
(i.e. the time period over which we believe data
can reliably extrapolated) but we will explore in
a sensitivity analysis the impact of conducting a
longer (e.g. lifetime) time horizons. The
perspective will be that of the UK NHS and
patients and discounting in the base case will
be at 3.5% [44].
The parameter estimates (probabilities, costs and
utilities) required for the model will come from the
longitudinal study described above, focused searches
of the literature and advice from an expert panel. All
uncertainty surrounding estimates of input
parameters will be informed by appropriate
distributions calculated from the longitudinal study
or the literature. The results of the economic model
will be presented as incremental costs and QALYs,
and the incremental cost per QALY gained. Both
deterministic and probabilistic sensitivity analyses
will be carried out to test and explore uncertainties.
The results of the probabilistic sensitivity analysis
will be presented as a series of cost-effectiveness
acceptability curves (CEACs). At the end of the
modelling process recommendations for service
change will be available for evaluation and further
research.
Ethical approval
This study has approval from the Yorkshire and the
Humber (Leeds West) Ethics Committee (Ref: 12/YH/0338)
and NHS R&D approval from each participating site.
Honorary NHS contracts have been issued where
necessary.
Discussion
Currently there are data, which suggest that patients
with COFP use a large amount of healthcare resource
[13-17]. What is unknown, and this study seeks to identify,
is if the resource that is used is proportional and effective
for their complaint?
It is conceivable that the only reason COFP patients
use so much resource is because the care system they
experience fails to provide them with clear and defined
pathways of care based upon early diagnosis and appropri-
ate management. The need for early diagnosis and
management is key given that those with a propensity for
developing psychological comorbidities may develop these
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sooner if diagnosis is delayed or there is a misdiagnosis
causing uncertainty or anxiety over the nature of
the complaint [5,45,46]. Any psychological comorbidi-
ties that develop will then negatively impact on their
prognosis [23,47-49].
Early appropriate conservative management [50] is also
important given the emerging role for central sensitisation
[51-57] and the autonomic nervous system (ANS) in COFP
[58]. Reducing the peripheral afferent barrage at the earliest
opportunity and down regulating any dysfunctional ANS as
soon as possible through early diagnosis, reassurance, and
management will also all hopefully reduce the chance
of central neuroplastic changes, “central sensitisation”
[51,59]. Reducing the potential for central sensitisation, or
up regulation of the ANS, occurring may then help im-
prove the success of (simpler) therapies, reduce treat-
ment times, and improve prognosis by reducing the
potential for the condition becoming chronic.
There are clear and evidence-based methods for
managing generic chronic pain in an interdisciplinary
fashion of which a substantial proportion may be
translatable into COFP [60,61]. A recent national pain
audit [21] in the U.K. has, however, highlighted the
difficulty in establishing the provision of such a service for
generic chronic pain management nationwide, irrespective
of the need for a condition specific service. The same
audit also highlighted that despite the evidence base
supporting interdisciplinary pain management, it is still
unclear how to clinically and cost effectively provide
(NHS) healthcare services for patients with chronic pain
[21]. Against the background of changes in commissioning
and the drive to provide services more cost-effectively in the
NHS [62] the DEEP study may provide answers for COFP
care pathways and also a model and methodology by which
to examine other long-term conditions’ care pathways.
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